drugset / Trial / NCT06611826
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
NaSingle-groupOpen-labelTreatment
Summary
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent nasopharyngeal carcinoma.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2028-09-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carelizumab | Unknown | 200 mg | — |
| Subject | Endostar | Protein / enzyme biologic | 150 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1 g | — |